R & D labs often seek to define and improve production processes. While a well-written protocol spells out a process like a favorite recipe, few standards exist for exchanging process designs and associated experimental data in a more structured fashion. This talk showcases Riffyn's web-based tools for collaborative process design and experimental analysis.
Value tends to accrue to people and organizations that can reduce uncertainty.
The place where you can do magic is where you clear the cloud of uncertainty and turn that into something usable. That’s why data scientists are in demand and hold such a powerful role, because they have the potential to reduce uncertainty.
People make bad decisions because they have inadequate information to make good decisions.
I started Riffyn to solve this with computer aided design (CAD), statistical data and an analytics approach to science experimentation.
Riffyn was mentioned in a front page article in the WSJ - solving the breakdown in biomedical research.
"Some companies also have stepped into the gap...Riffyn in Oakland, Calif., is another specialized firm in this niche, with software that helps scientists to map out their experiments, manage scattered data sets, pull it all together for analysis and share it with colleagues."
During the SynBioBeta SF conference last October, Riffyn announced the launch of its cloud-based research process design software. The company’s mission to change the pace of research and development through software innovation has now reached new speeds through a key partnership with Novozymes, the largest provider of enzyme and microbial technologies worldwide. The industrial giant will deploy and develop Riffyn’s software, implementing it progressively across Novozymes’ 1000-person global R&D organization to support product development.
An article by Synbiobeta delves into the issues of data fragmentation, data analysis and tech transfer in life sciences R&D - with interviews of Chris Stevens, the Director of Strategy, Operations and Planning at GSK, and with Tim Gardner, Riffyn's CEO. From the post:
Today, more resources than ever before are being channeled into life sciences R&D. In recent years, annual worldwide industrial life science R&D spending has exceeded $160 billion and is expected to continue to grow, with government and nonprofit spending on life sciences adding another $60-70B annually to this total. But, contrary to expectations, the influx of support doesn’t mean that researchers’ jobs are getting any easier—and in fact, in some ways they are getting much harder. Read more at synbiobeta.com.
The O'Reilly Radar Podcast: Tim Gardner on the synthetic biology landscape, lab automation, and the problem of reproducibility.
Tech funders warm to start-ups that use microbes in manufacturing.
Interview by Babak Mozooni at Technomat
In a post on the PLOS Tech Blog, Riffyn engineer Marcus Carr discusses an open source collaboration between PLOS and Riffyn to create a living, crowd-sourced ontology of scientific resources and terms. Such shared terminology is as fundamental to the progress of science as language is to human progress.
BioTechniques reviews the recent history of reproducibility issues in scientific research, and profiles organizations, including Riffyn, that are helping to bring about change for the better.
Resource Miner is an open project to develop a natural language processing toolkit for extracting controlled vocabularies (ontologies) of research resources used in the scientific literature, and organizing them into an associative knowledge graph. Riffyn has sponsored this project in collaboration with PLOS and Mozilla Science Lab. The Mozilla Science Lab helps a global network of researchers, tool developers, librarians and publishers collaborate to further science on the web. Find out more and contribute to the ResourceMiner project here.
Motley fool highlights the problems of reproducibility in science and discusses Riffyn as one of the crop of startups that aims to upend that long-standing problem.
After having spent time in a lab, one problem that strikes you is how archaic they are in their methods of operation. Adapting to new technologies and workflow habits is not something that science has embraced in that past. Thankfully there are others that feel the same way and are doing something to change this, such as Riffyn.
Jenn Webb from O'Reilly Radar interviews Riffyn Founder/CEO Tim Gardner, touching on regulatory issues around synthetic biology, and also Riffyn's vision for improving research reproducibility through the application of the quality approaches that have transformed manufacturing.
In a Radar blog post, O'Reilly's Mike Loukides discusses the new tools and platforms (including Riffyn) which are seeking to update scientific methodology for the digital age and in doing so address the reproducibility problem.
As a member of the European Union Scientific Committees working group on Synthetic Biology, Riffyn is helping to define the field of Synthetic Biology and assess its benefits, risks, and research needs. This editorial outlines the work to-date and seeks public comment.
In the 3rd December 2014 issue of Nature, Erica Check Hayden looks at a new generation of life science startups, including Riffyn, which are aiming to revolutionise how science is done, and to make it more reliable in the process.
In an editorial in Science, Riffyn's founder discusses irreproducibility: the "ugly ducking of science," and how process technologies, quality methods and modern web technologies could turn it into a "Swan."